导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 20.72% | 375/4773 |
| 近一周 | 0.20% | 730/5465 |
| 近一月 | -6.62% | 4246/5421 |
| 近一季 | -19.69% | 4904/5231 |
| 近半年 | 18.04% | 278/4920 |
| 近一年 | 27.10% | 288/4394 |
| 近两年 | 108.92% | 557/2954 |
| 近三年 | 71.70% | 327/2253 |
| 成立以来 | 110.00% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.86% 2530/4961 |
66.12% 330/5312 |
- - |
- - |
| 2025 | 38.55% 864/4813 |
-2.43% 2886/3635 |
2.63% 1457/4076 |
32.12% 1093/4524 |
4.73% 497/4813 |
| 2024 | 7.23% 1680/3463 |
-0.99% 1162/2808 |
-2.78% 1250/3014 |
15.94% 1588/3129 |
-3.92% 2405/3463 |
| 2023 | -24.68% 1971/2656 |
-0.63% 1810/2280 |
-4.36% 1149/2385 |
-16.44% 2255/2515 |
-5.16% 1276/2655 |
| 2022 | -27.77% 1508/2207 |
-18.36% 1324/1919 |
7.42% 480/2016 |
-15.99% 1385/2113 |
-1.96% 1761/2208 |
| 2021 | 18.94% 202/1822 |
-6.23% 989/1255 |
34.01% 31/1330 |
-7.05% 1017/1466 |
1.83% 786/1822 |
| 2020 | 89.97% 23/1250 |
6.63% 40/1028 |
34.65% 23/1067 |
6.29% 859/1164 |
24.48% 35/1184 |
| 2019 | - - |
- - |
- - |
6.42% 127/850 |
7.63% 418/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏创业板成长ETF联接C VS. 长安沪深300非周期A(740101) |